CK Hutchison-backed Sequencio to Release Preclinical Data on Cancer Vaccine, Combination Therapy Significantly Slows Tumor Growth

Sequencio Therapeutics, a subsidiary of CK Hutchison Holdings, has announced that it will present preclinical data for its cancer vaccine candidates CKLS118 and CKLS202 on Friday at the Society for Immunotherapy of Cancer (SITC) annual meeting in Phoenix, Arizona, US. The company's research found that when its circular RNA cancer vaccine CKLS118 is used in combination with a PD-1 inhibitor, the tumor growth inhibition rate reaches up to 88.9%, compared to 68.6% when the PD-1 inhibitor is used alone.